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A B S T R A C T
Vitamin K epoxide reductase (VKOR) is a key enzyme in the g-carboxylation of proteins associated with important
bodily functions (coagulation, bone metabolism, etc.). This feature is particularly used in warfarin therapy, which blocks
the VKOR enzyme and leads to production of dysfunctional coagulation proteins. Genetic factors, particularly vitamin K
epoxide reductase complex 1 (VKORC1) gene, have greatest influence on warfarin therapy. The aim of this study was to
determine the distribution of VKORC1 1173C>T and VKORC1 -1639G>A polymorphisms, which are most important
for warfarin therapy. We investigated 420 unrelated healthy individuals, mostly blood donors, from region of the Eastern
Croatia. Both investigated polymorphisms were in perfect linkage disequilibrium (LD) and showed identical results. 151
patients (36%) were homozygous for the wild-type (C/C and G/G), 196 (47%) were heterozygous (C/T and G/A) and 73
(17%) were homozygous for the variant allele (T/T and A/A). Number of normal alleles among individuals was 498
(59.3%), and number of variant alleles was 342 (40.7%). The data obtained are in good agreement with the results of
studies in other European populations.
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Introduction
Vitamin K is generic name for several related com-
pounds with similar structure (phylloquinone [K1], me-
naquinone [K2] and menadione [K3])
1,2. Vitamin K acts as
a cofactor to g-Glutamyl carboxylase (GGCX), an enzyme
that catalyzes posttranslational carboxylation of particu-
lar glutamic acid (Glu) to g-carboxyglutamic acid (Gla) in
number of body proteins, which is essential for their
proper biological function. When reduced form of vita-
min K (vitamin K hydroquinone – KH2) participate in
g-carboxylation, it is simultaneously oxidized to vitamin
K 2,3-epoxide (K>O). Due to the very limited amount of
available vitamin K in the body, prompt reduction of
K>O in vitamin K active form (KH2) is required in order
to maintain g-carboxylation. This process, also known as
the vitamin K cycle, is achieved with help of Vitamin
K-epoxide reductase (VKOR), a key enzyme in recycling
of available stocks of vitamin K1–4. It was observed that
precisely this process of reduction of K>O is rate-limit-
ing step in process of g-carboxylation5,6. VKOR primarily
catalyzes de-epoxidation of K>O to vitamin K, while,
probably, some other enzymes catalyze reduction of vita-
min K to KH2 in vivo
5.
Availability of reduced vitamin K is essential for pro-
per function of some very important body proteins (also
known as vitamin K dependent proteins). Those proteins
are: coagulation factor and proteins (FII, FVII, FIX, FX,
Protein C, S and Z), bone metabolism proteins (matrix
Gla proteins [MGP] and osteocalcin, which is main non-
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colagen protein of bone matrix and is associated with the
mineralized matrix of bone)1,7 and cell proliferation and
apoptosis proteins (growth arrest specific gene 6 product
[GAS6])1,3–5,8,9. Inadequate availability of vitamin K leads
to insufficient g-carboxylation of vitamin K dependent
proteins, which results in formation of partially carbo-
xylated or non-carboxylated proteins10. Biological activ-
ity of those proteins is usually significantly reduced.
Impact of reduced vitamin K availability on function
of coagulation proteins is utilized in oral anticoagulation
therapy. 4-hydroxycoumarin anticoagulants exert their
anticoagulant action by blocking VKOR enzyme, which
result in decreased amount of reduced vitamin K and,
consequently, in production of hypofunctional or non-
-functional coagulation factors1,4,10,11. Warfarin is the most
used 4-hydroxycoumarin anticoagulant, and most used
oral anticoagulant worldwide12. It is commonly prescri-
bed for prevention and treatment of thrombotic disor-
ders10,11,13–15. Therapeutic effect of warfarin can be di-
rectly evaluated by monitoring of prothrombin time
which is expressed as international normalized ratio
(INR) units. Therapeutic range is usually kept between 2
and 3 INR, in most cases10. Although proven very effec-
tive, warfarin dosage is extremely challenging due to it’s
very narrow therapeutic index and wide interindividual
variability10,13,16. Some of factors that influence warfarin
response are: nutrition (vitamin K intake), some con-
comitant diseases, drug-drug interactions and, with
greatest influence, genetic factors10,13,17.
Researchers performing Genome-Wide Association Stu-
dies (GWAS) determined that single nucleotide polymor-
phisms (SNPs) of two genes have greatest influence on
warfarin dose18,19. First gene is CYP2C9 (OMIM 601130),
which encodes hepatic microsomal enzyme cytochrome
P450 2C9, and whose activity represents the major route
of metabolism of warfarin20–22. Most important CYP2C9
alleles for warfarin therapy are CYP2C9*1 (wild-type al-
lele, most common in the population), CYP2C9*2, (430C
>T) and CYP2C9*3 (1075A>C)9,23–25. Individuals with
CYP2C9*2 and CYP2C9*3 alleles have lower warfarin
dose requirements and are more susceptible to over-
anticoagulation and bleeding complications23,25,26. Sec-
ond gene, named vitamin K epoxide reductase complex
subunit 1 gene (VKORC1 – OMIM 608547), was discov-
ered recently (in 2004) by two independent teams27,28.
VKORC1 gene is located on short arm of chromosome 16,
its spans 5139 base pairs and encodes a 163 amino acid
integral membrane protein – VKOR enzyme responsible
for regeneration of vitamin K29. Association of VKORC1
SNPs with the therapeutic dose of warfarin was observed
soon after the discovery of the gene30–32. Although multi-
tudes of VKORC1 SNPs were tested for association with
warfarin therapy, only few of them showed positive cor-
relation with warfarin dose and also significant minor al-
lele frequency (MAF) in population. Several authors at-
tempted to explain VKORC1 polymorphisms influence
on warfarin dose by combining them into haplotypes31,33.
Later researches showed that all VKORC1 haplotypes
could be replaced with only two SNPs which explain al-
most all of dose variability31,34–36. Those SNPs are VKORC1
1173C>T (rs9934438) and VKORC1 -1639G>A
(rs9923231)18,34,35. VKORC1 1173C>T represents nucle-
otide substitution in first intron of VKORC1 and it was
first SNP associated with lower doses of warfarin30,33.
VKORC1 -1639G>A is a SNP taking place in promoter
region of VKORC1 gene at the second nucleotide in
E-box. This polymorphism impacts transcription factor
binding site which affects expression of gene and carriers
of variant alleles had lower values of mRNA and presum-
ably fewer functional copies of VKORC protein31,37,38. It
was observed that carriers of VKORC1 1173C>T and
VKORC1 -1639G>A variant alleles require significantly
lower doses of warfarin, compared with normal, wild-
-type homozygote. Also, some authors observed an asso-
ciation of VKORC1 polymorphisms (-1639G>A and
1173C>T) with an increased risk of adverse effects in
therapy (INR>4, bleeding etc.)39–43, time needed to reach
the target INR, time spent above the therapeutic INR44,45
or below therapeutic INR46. One of most important find-
ings was that VKORC1 SNPs frequencies in population
vary significantly depending on race and ethnicity36,47.
The aim of this study was to determine variant allele
frequency distribution of two VKORC1 polymorphisms:
VKORC1 1173C>T (rs9934438) and VKORC1 -1639G
>A (rs9923231) in Croatian population and to find out if
they are in linkage disequilibrium (LD) like in other
populations32,36,37,41,48,49.
Subjects and Methods
This study included 420 unrelated healthy individu-
als: 269 male and 151 female, aged 21–79 (median age
41), predominantly blood donors, from region of Eastern
Croatia. Study was performed according to Declaration
of Helsinki. During the recruiting process, all subjects
were informed about the purpose of this study and they
all signed informed consent. Ethical Committee of the
Institute of Public Health for Osijek-Baranja County and
Ethical Committee of the University Hospital Centre
Osijek approved this study.
A 5 ml peripheral blood sample was collected from
each participant into Vacutainer EDTA containing tubes
(Becton Dickinson, Erembodegem, Belgium). Genomic
DNA was isolated from peripheral leukocytes from anti-
coagulated whole blood using High Pure PCR Template
Preparation Kit (Roche, Mannheim, Germany), accord-
ing to manufacturer instructions.
Real-time PCR instrument Light Cycler 1.5 (Roche,
Mannheim, Germany) was used for detection of polymor-
phisms. Genotyping for VKORC1 1173C>T and VKORC1
-1639G>A was achieved using LightMix for the detec-
tion of human VKORC1 C1173T and VKORC1 G-1639A
detection kits (TIB Molbiol, Berlin, Germany). Melting
curve analysis was performed to distinguish between
polymorphisms. Positive and negative controls were in-
cluded in each run and random 10% of samples were
re-analyzed with 100% concordance with previous analy-
ses.
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Allele frequencies were estimated by gene counting.
Hardy-Weinberg equilibrium testing, c2 and Fisher’s ex-
act tests were performed using R software version 2.15.3
(http://www.r-project.org/). Significance level of 0.05 was
used for all tests.
Results
Total of 420 individuals were analyzed to determine
polymorphisms distribution of VKORC1 1173C>T and
VKORC1 -1639G>A single nucleotide polymorphisms
(SNPs) in population of Eastern Croatia. Both polymor-
phisms were in perfect LD, and showed identical results
in our study. 151 individuals (36%) were homozygous for
wild type (C/C and G/G), 196 (47%) were heterozygous
(C/T and G/A) and 73 (17%) were homozygous for muta-
tion (T/T and A/A). Allele distribution was as follows: 498
alleles (59.3%) were normal alleles (C and G) and 342 al-
leles (40.7%) were mutated alleles (T and A). All geno-
types were in Hardy-Weinberg equilibrium (p=0.495).
We have also analyzed distribution of VKORC1 1173C
>T and VKORC1 -1639G>A according to gender. Among
male individuals 103 of them (38%) were homozygous for
wild type (C/C and G/G), 124 (46%) were heterozygous
(C/T and G/A) and 42 (18%) were homozygous for muta-
tion (T/T and A/A). Among female individuals 48 of them
(32%) were homozygous for wild type (C/C and G/G), 72
(48%) were heterozygous (C/T and G/A) and 31 (21%)
were homozygous for mutation (T/T and A/A). There
were no statistically significant differences in polymor-
phisms distribution in relation to gender (c2=2.534; p=
0.282). Obtained results are in concordance with pub-
lished results for European Caucasian population. World-
wide VKORC1 1173C>T and VKORC1 -1639G>A poly-
morphism distribution is presented in Table 1.
Discussion
Large proportion of interindividual and interethnical
variability in warfarin response can be attributed to ge-
netic factors which regulate pharmacokinetics and phar-
macodynamics of drug. VKORC1 SNPs can contribute up
to 37% of complete variability50. It is known that warfa-
rin dose requirements vary across ethnic groups world-
wide.
Clinical observations shows that individuals of Asian
descent require lower doses, while individuals of African
descent require higher doses of warfarin, compared to
population of European descent51,52. This can be ex-
plained with distribution of VKORC1 1173C>T and
VKORC1 -1639G>A variant alleles between different
ethnic groups. As it can be seen from Table 1, frequency
of variant allele (T and A), which is marker of low warfa-
rin dose phenotype, in Asian populations is predominant.
Among Chinese, Japanese and Korean it accounts for
over 90% of all alleles53–55. This very high proportion of
low dose phenotype allele could explain lower dose re-
quirements among Asians. Only exception in Asia is In-
dian population, which displays completely different fre-
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TABLE 1
VKORC1 1173C>T AND VKORC1 -1639G>A VARIANT ALLELE














Croatian 420 40.7 –
Present
study
Austrians 206 43.0 0.605 64
Danes 244 41.8 0.806 65
French 115 41.3 0.915 67
Germans 200 41.5 0.862 33
Greek 98 48.5 0.175 68
Hungarians 510 39.0 0.638 69
Italian 147 39.8 0.922 30
Dutch 1525 39.3 0.329 66
Norwegians 212 36.6 0.344 48
Romanians 332 42.2 0.710 70
Slovenians 165 43.3 0.577 71
Spaniards 175 41.4 0.927 72
Turks 292 40.4 0.938 73
UK (English) 297 47.3 0.080 49
South America
Argentines 101 50.5 0.092 62




300 10.8 <0.001 58







Africa & Middle East
Egyptians 200 72.3 <0.001 59
Iranians 126 55.6 <0.001 60




Izrael (Jew) 162 57.4 <0.001
South Afri-
cans (Black)
993 3.5 <0.001 57
Asia
Chinese 178 91.6 < 0.001 53
Indian 102 14.2 < 0.001 56
Japanese 341 91.8 < 0.001 54
Korean 265 94.0 < 0.001 55
* Fisher’s exact test – frequency of variant allele (T and A) of
Croatian vs. other populations
quency distribution: only around 14% are carriers of
variant allele56.
On the other hand, in black Africans population and
populations of African origin (e.g. African-American), al-
most over 90% of individuals are carriers of normal allele
and only up to 10% of variant allele57,58, which could ex-
plain higher warfarin dose requirements in black popula-
tions compared to Asians and Caucasians. Regarding
other African nations that have been investigated, Egyp-
tians are similar to Asian model (over 70% are carriers of
variant allele)59. In region of Middle East, VKORC1
1173C>T and VKORC1 -1639G>A variant allele fre-
quencies from different populations are also available60,61.
In South America, Argentinian and Brazilian popula-
tion variant allele frequencies are similar to European
population distribution62,63. In North America, among
African-American population variant allele frequency is
10.8%, while among Asian-American population variant
allele frequency is 66.7%. Caucasian population and His-
panics exhibit same variant allele distribution as Europe-
ans (variant allele frequency around 41%)58.
Among European populations tested for VKORC1
1173C>T and VKORC1 -1639G>A polymorphisms, al-
most all showed similar frequency of variant allele (36.6
– 48.5%)30,33,48,49,64–73.
In our study, we have found that frequency of variant
allele in population of Eastern Croatia is 40.7%. When
compared to other European populations, there is no sta-
tistically significant difference (Fisher’s exact test, p>
0.05) between VKORC1 1173C>T and VKORC1 -1639G>A
variant allele distribution of Croatian population and
those of other European populations (see Table 1). There
were also no significant differences compared to South
American and North American Caucasian and Hispanics
populations. Statistically significant difference (Fisher’s
exact test, p<0.05) was observed when Croatian popula-
tion was compared to Asian (and Asian-American), Afri-
can (and African-American) and Middle East popula-
tions.
Conclusion
To the best of our knowledge, this report is first to ad-
dress frequency distribution of VKORC1 1173C>T and
VKORC1 -1639G>A polymorphisms in Croatian popula-
tion. Distribution found in our study is in good agree-
ment with those found in other European populations.
Our results confirms that VKORC1 1173C>T and
VKORC1 -1639G>A are in perfect LD in Croatian popu-
lation, similar to results of other studies conducted on
Caucasian and Asian populations32,36,37,41,48,49. Conside-
ring those results, future studies of above mentioned
polymorphisms in Croatian population should be limited
to genotyping only one of them.
According to our data, 47% of Croatian population are
carriers of one variant VKORC1 1173C>T and VKORC1
-1639G>A allele, which means that those individuals
will have up to 36% lower warfarin dose require-
ments38,49,74. Another 17% are homozygous for variant al-
lele, which means that those individuals will have up to
60% lower dose requirements38,49,74. This could imply
that those individuals will probably be more prone to
overanticoagulation and adverse events. With knowledge
of VKORC1 genotype data before commencing of ther-
apy, and with combining them with CYP2C9 genotype
data and other clinical and environmental factors, warfa-
rin dose could be adjusted which could prevent occur-
rence of adverse events.
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POLIMORFIZMI VITAMIN K EPOKSID REDUKTAZA KOMPLEKS 1 (VKORC1) GENA
U POPULACIJI ISTO^NE HRVATSKE
S A @ E T A K
Vitamin K epoksid reduktaza (VKOR) je klju~an enzim u g-karboksilaciji proteina povezanih s va`nim tjelesnim
funkcijama (koagulacija, metabolizam kostiju i dr.). Ta zna~ajka je posebno iskori{tena u terapiji varfarinom koja blo-
kira VKOR enzim i uzrokuje stvaranje nefunkcionalnih koagulacijskih proteina. Na terapiju varfarinom najve}i utjecaj
imaju genetski ~imbenici, posebno vitamin K epoksid reduktaza kompleks 1 (VKORC1) gen. Cilj ovog istra`ivanja bio je
utvrditi raspodjelu dvaju polimorfizama najzna~ajnijih za terapiju varfarinom: VKORC1 1173C>T i VKORC1 -1639G>A.
Ispitano je 420 zdravih osoba, prete`no dobrovoljnih davatelja krvi, iz podru~ja isto~ne Hrvatske. Rezultati su pokazali
da su oba ispitivana polimorfizma u savr{enoj neravnote`i povezanosti (eng. linkage disequilibrium – LD) i pokazali su
identi~ne rezultate. Za 151 ispitanika (36%) potvr|eno je da su homozigoti za divlji tip (C/C i G/G), 196 ispitanika (47%)
su heterozigoti (C/T i G/A) a 73 (17%) su homozigoti za varijantni alel (T/T i A/A). Broj normalnih alela me|u ispita-
nicima bio je 498 (59,3%), dok je varijantnih alela prona|eno 342 (40,7%). Dobiveni podaci se dobro sla`u s rezultatima
studija u drugim Europskim populacijama.
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